Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN
Year: 2026
Type: article
Abstract: BACKGROUND: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. METHODS: In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. RESULTS: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. CONCLUSIONS: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
Authors: Carla M. Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C.A.J. Van De Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Eli Khankin, Zhongshen Wang, Elena Surova, Johan Szamosi, Fadi Fakhouri
Institutions: University of Iowa, University of Iowa Stead Family Children’s Hospital, Columbia University Irving Medical Center, Vall d'Hebron Hospital Universitari, Centre Hospitalier Universitaire de Bordeaux, University of Colorado Anschutz, University College London, Emory University, Yonsei University, The University of Queensland, Princess Alexandra Hospital, University of Toronto, Hospital for Sick Children, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Nagoya University, Hospital Geral de Bonsucesso, Imperial College London, Mario Negri Institute for Pharmacological Research, Radboud University Medical Center, Amalia Kinderziekenhuis, Bambino Gesù Children's Hospital, Arkana Laboratories, Royal Manchester Children's Hospital, University Hospital Regensburg, Centre Hospitalier Universitaire de Montpellier, Hôpital Lapeyronie, Schneider Children's Medical Center, Guy's and St Thomas' NHS Foundation Trust, Evelina London Children's Healthcare, Biogen (United States), Swedish Orphan Biovitrum (Sweden), Centre Hospitalier Universitaire Vaudois, University of Lausanne
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7225989856
